GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Sanofi to acquire Dren Bio's immunology unit - Finance news and analysis from Global Banking & Finance Review
Finance

Sanofi to acquire Dren Bio's immunology unit

Published by Global Banking & Finance Review

Posted on March 20, 2025

1 min read

· Last updated: March 20, 2025

Add as preferred source on Google

Sanofi Acquires Dren Bio's Autoimmune Unit for $600 Million

(Reuters) - Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.

The French healthcare group will acquire the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and potential future payments totalling $1.3 billion, it said in a statement.

The transaction is expected to close in the second quarter of 2025, it added.

(Reporting by Alban Kacher)

Key Takeaways

  • Sanofi to acquire Dren Bio's autoimmune unit DR-0201.
  • The deal includes an upfront payment of $600 million.
  • Potential future payments could total $1.3 billion.
  • The transaction is expected to close in Q2 2025.
  • Sanofi expands its immunology portfolio with this acquisition.

Frequently Asked Questions

What is the main topic?
The main topic is Sanofi's acquisition of Dren Bio's autoimmune unit DR-0201 for $600 million upfront, with potential future payments totaling $1.3 billion.
What is the value of the deal?
The deal includes an upfront payment of $600 million, with potential future payments totaling $1.3 billion.
When is the transaction expected to close?
The transaction is expected to close in the second quarter of 2025.

Related Articles

More from Finance

Explore more articles in the Finance category